Arch Development Corporation

Geron Corporation

The University of Chicago

Mark J Ratain

Calvin B Harley

Laurence Elias

Jennifer Smith

Anna Di Rienzo

Fabio Benedetti

Lalitha Iyer

Federico Innocenti

Elora Gupta

Carrie Grimsley

The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.

Method for identification of sensitivity of a patient to telomerase inhibition therapy

The present invention concerns the methods and compositions for evaluating the risk of ironotecan toxicity in a cancer patient based on the genotype of the patient at position &#x2212;3156 of the UGT1A1 gene or at any position in linkage disequilibrium with the &#x2212;3156 variant.

Methods for predicting irinotecan toxicity

The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Methods for detection of promoter polymorphism in a UGT gene promoter

The present invention is, directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

This invention provides methods and combination formulations and kits to reduce the toxicity of camptothecin drugs, such as irinotecan (CPT-11). Disclosed are therapeutics and treatment methods employing such drugs in combination with agents that increase conjugative enzyme activity or glucuronosyltransferase activity, and agents that decrease biliary transport protein activity, such as cyclosporine A, the resultant effects of which are to decrease the significant side effects previously associated with treatment using these drugs.

Growing community of inventors

Chicago, IL, United States of America

Mark J Ratain